ZNF671のDNAメチル化は漿液性卵巣がん早期再発の予測因子である<要約> by Shoko Mase
  
Nagoya City University Academic Repository 
 
 
 
学 位 の 種 類 
 
 
  博士 (医学) 
 
報 告 番 号 
 
  甲第１６９１号 
 
学 位 記 番 号   第１２０８号 
 
氏    名 
 
 
  間瀨 聖子 
 
 
授 与 年 月 日 
 
 
  平成 31年 3月 25日 
 
 
 
 
 
学位論文の題名 
 
 
 
 
 
ZNF671 DNA methylation as a molecular predictor for the early 
recurrence of serous ovarian cancer 
(ZNF671の DNAメチル化は漿液性卵巣がん早期再発の予測因子である） 
 
Cancer Science 2019; 
 
 
 
 
論文審査担当者 
 
 
  主査： 稲垣 宏 
  副査： 加藤 洋一, 杉浦 真弓 
 
 
<Background> Serous ovarian cancer is the most frequent type of epithelial 
ovarian cancer. Despite the use of surgery and platinum-based chemotherapy, 
many patients suffer from recurrence within 6 months, termed platinum 
resistance. Currently, the lack of relevant molecular biomarkers for the 
prediction of the early recurrence of serous ovarian cancers is linked to the 
poor prognosis.  
<Method> To identify an effective biomarker for early recurrence, we analyzed 
the genome-wide DNA methylation status characteristic of early recurrence 
after treatment.  
<Result> The patients in The Cancer Genome Atlas (TCGA) dataset who showed a 
complete response after the first therapy were categorized into 2 groups: 
early recurrence serous ovarian cancer (ERS, recurrence ≤12 months, n = 51) and 
late recurrence serous ovarian cancer (LRS, recurrence >12 months, n = 158). 
Among the 12 differently methylated probes identified between the 2 groups, 
we found that ZNF671 was the most significantly methylated gene in the early 
recurrence group. A validation cohort of 78 serous ovarian cancers showed 
that patients with ZNF671 DNA methylation had a worse prognosis (P < .05). The 
multivariate analysis revealed that the methylation status of ZNF671 was an 
independent factor for predicting the recurrence of serous ovarian cancer 
patients both in the TCGA dataset and our cohort (P = .049 and P = .021, 
respectively). Functional analysis revealed that the depletion of ZNF671 
expression conferred a more migratory and invasive phenotype to the ovarian 
cancer cells. 
<Conclusion> Our data indicate that ZNF671 functions as a tumor suppressor in 
ovarian cancer and that the DNA methylation status of ZNF671 might be an 
effective biomarker for the recurrence of serous ovarian cancer after 
platinum-based adjuvant chemotherapy. 
 
